Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of rivaroxaban or dabigatran on microparticle formation in critically ill patients versus matched healthy subjects
2011-002084-20Phase 4Terminated
- Sponsor
- Medical University of Vienna
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in critical illness comparing Rivaroxaban 10 mg arm with Dabigatran 110 mg arm (2 arms). Primary endpoint: Plasma microparticle concentrations. Started Jun 2011; status: terminated.
02
Drugs
rivaroxabandabigatran
03
Conditions
critical illness
Beyond the preview
Go deeper on 2011-002084-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002084-20.